AI Summary
✦ ClarthaGlaxoSmithKline Pharmaceuticals is a pharmaceutical manufacturer and distributor serving India and international markets. Vaccines, respiratory specialty medicines, and general medicines drive revenue, led by Shingrix, NUCALA, Trelegy Ellipta, Augmentin, and Ceftum. First-quarter profit rose 16% to ₹237 crore, supporting 11.7% profit growth despite only 2.2% revenue growth and indicating improving margins. ROE is unavailable, while debt-to-equity of 1.47 means leverage can amplify reported returns and financial risk. Earnings growth currently exceeds revenue growth, suggesting mix and operating-margin gains rather than broad-based volume expansion. At 41.2 times earnings, the shares appear rich and trade at a premium to the company’s low-single-digit revenue growth. Positive sentiment may persist, but valuation leaves limited room for execution setbacks, pricing pressure, or weaker vaccine and respiratory demand.
Price Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 4 analysts
Fundamentals
Fundamentals institutional score is 81 using growth durability 81.0.
Valuation
Valuation institutional score is 35 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 75 using mean target upside 18.5%; dispersion penalty 8.2; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 66 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 7 recent ticker-linked news items.
Signal Summary
Market intelligence remains Neutral. fundamentals and analyst consensus provide support, while valuation and market sentiment remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 7.8% above historical median. Valuation is stable — currently in the overvalued zone (z-score: +0.61). Confidence: 81%.
Live forward EPS implies next-12-month EPS of ₹78.88. Applying the stock's normalized valuation corridor produces a fair range of ₹2,633.01 to ₹3,292.45, with base value near ₹3,010.06 (+15.7% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹78.88
Forward P/E
33.0x
Base Fair Value
₹3,010.06
Fair Range
₹2,633.01 - ₹3,292.45
Upside To Base
+15.7%
Estimate Source
Live forward EPS
Growth Estimate
+15.7%
5Y Average
30.93
Current
41.15
Overvalued
41.74
Undervalued
33.38
5Y Average
23.35
Current
31.08
Overvalued
30.08
Undervalued
15.81
5Y Average
8.37
Current
11.14
Overvalued
10.78
Undervalued
5.67
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
DR. REDDY S LABORATORIES DRREDDYPharmaceuticals | -5.6% | 10.0% | 29.2x Undervalued | -40% vs avg | -3.9% |
DABUR INDIA LTD DABURFMCG - Personal Products | +10.6% | 14.6% | 37.3x Undervalued | -24% vs avg | -19.6% |
APOLLO HOSPITALS ENTER. L APOLLOHOSPHospitals & Diagnostic Centres | +18.1% | 7.7% | 66.0x Premium | +35% vs avg | +23.2% |
CIPLA LTD CIPLAPharmaceuticals | +3.5% | 12.0% | 35.2x Undervalued | -28% vs avg | -2.7% |
EICHER MOTORS LTD EICHERMOTTrucks & Buses | +31.5% | 23.2% | 38.0x Undervalued | -22% vs avg | +41.4% |
BSE LIMITED BSEStock Exchanges & Ratings | +64.0% | 48.9% | 52.3x Fair | +7% vs avg | +44.3% |
HERO MOTOCORP LIMITED HEROMOTOCOTwo Wheelers | +34.9% | 10.7% | 21.5x Undervalued | -56% vs avg | +25.5% |
CG POWER AND IND SOL LTD CGPOWERHeavy Electrical Equipments | +14.0% | 9.8% | 111.1x Premium | +128% vs avg | +32.2% |
GLAXOSMITHKLINE PHARMA LT trades at a discount (41.2x vs peer avg 48.8x), suggesting potential undervaluation relative to the Pharmaceuticals cohort. Peers include DR. REDDY S LABORATORIES, DABUR INDIA LTD, APOLLO HOSPITALS ENTER. L — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹924 CrJun 2026Latest net profit
₹253 CrJun 2026Latest EPS
₹14.95Jun 2026Net margin
32.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 738 | 953 | 805 | 911 | 811 | 1,000 | 946 | 966 | 805 | 974 | 1,023 | 989 | 924 |
| Expenses + | 597 | 667 | 587 | 656 | 582 | 681 | 656 | 635 | 554 | 639 | 655 | 642 | 631 |
| Operating Profit | 141 | 287 | 218 | 255 | 229 | 319 | 290 | 331 | 251 | 335 | 368 | 347 | 293 |
| OPM % | 19% | 30% | 27% | 28% | 28% | 32% | 31% | 34% | 31% | 34% | 36% | 35% | 32% |
| Other Income + | 54 | 28 | -135 | 32 | 36 | 37 | 35 | 39 | 44 | 34 | 32 | 36 | 62 |
| Interest | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 |
| Depreciation | 16 | 18 | 17 | 18 | 16 | 17 | 19 | 15 | 16 | 17 | 20 | 13 | 16 |
| Profit before tax | 179 | 297 | 65 | 269 | 248 | 339 | 306 | 355 | 279 | 351 | 378 | 369 | 338 |
| Tax % | 27% | 27% | 30% | 28% | 27% | 27% | 25% | 27% | 27% | 27% | 27% | 26% | 25% |
| Net Profit + | 131 | 216 | 45 | 193 | 182 | 249 | 229 | 260 | 205 | 255 | 277 | 275 | 253 |
| EPS in Rs | 7.71 | 12.72 | 2.69 | 11.40 | 10.72 | 14.68 | 13.49 | 15.36 | 12.08 | 15.05 | 16.36 | 16.23 | 14.95 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome